Cargando…

Biosimilar infliximab use in paediatric IBD

BACKGROUND: Biosimilar infliximab became available in the UK in 2015. Paediatric experience to date on its use is limited. We prospectively evaluated the safety and efficacy of biosimilar infliximab (Remsima) in two paediatric gastroenterology networks in patients with inflammatory bowel disease. ME...

Descripción completa

Detalles Bibliográficos
Autores principales:	Richmond, Lisa, Curtis, Lee, Garrick, Victoria, Rogers, Pam, Wilson, Michelle, Tayler, Rachel, Henderson, Paul, Hansen, Richard, Wilson, David C, Russell, Richard K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Drug Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754881/ https://www.ncbi.nlm.nih.gov/pubmed/28988215 http://dx.doi.org/10.1136/archdischild-2017-313404

Ejemplares similares

Paediatric clinical pharmacology in the UK
por: Choonara, Imti, et al.
Publicado: (2014)

Ciprofloxacin safety in paediatrics: a systematic review
por: Adefurin, Abiodun, et al.
Publicado: (2011)

Safety of ceftriaxone in paediatrics: a systematic review
por: Zeng, Linan, et al.
Publicado: (2020)

Infliximab in young paediatric IBD patients: it is all about the dosing
por: Jongsma, Maria M. E., et al.
Publicado: (2020)

Safety of new medicines in young children
por: Choonara, Imti
Publicado: (2011)

Drug use and upper gastrointestinal complications in children: a case–control study
por: Bianciotto, Manuela, et al.
Publicado: (2013)

Drug treatment of inborn errors of metabolism: a systematic review
por: Alfadhel, Majid, et al.
Publicado: (2013)

Acceptability of different oral formulations in infants and preschool children
por: van Riet-Nales, Diana A, et al.
Publicado: (2013)

Rational prescribing is important in all settings
por: Choonara, Imti
Publicado: (2013)

How safe is paracetamol?
por: Star, Kristina, et al.
Publicado: (2015)

Inter-individual variation in midazolam clearance in children
por: Altamimi, Mohammed I, et al.
Publicado: (2015)

Systematic review of the toxicity of short-course oral corticosteroids in children
por: Aljebab, Fahad, et al.
Publicado: (2016)

Lack of a significant change in caffeine metabolism in underweight children as determined by the caffeine breath test
por: Oshikoya, K A, et al.
Publicado: (2015)

Observational study on the palatability and tolerability of oral prednisolone and oral dexamethasone in children in Saudi Arabia and the UK
por: Aljebab, Fahad, et al.
Publicado: (2018)

Predictors of intravenous amiodarone induced liver injury
por: Diab, O.A., et al.
Publicado: (2017)

Additivity of nebivolol/valsartan single‐pill combinations versus other single‐pill combinations for hypertension
por: Ishak, Jack, et al.
Publicado: (2017)

Pharmacokinetic studies in children: recommendations for practice and research
por: Barker, Charlotte I S, et al.
Publicado: (2018)

Neonatal outcomes following new reimbursement limitations on palivizumab in Italy
por: Belleudi, Valeria, et al.
Publicado: (2018)

Safe and effective pharmacotherapy in infants and preschool children: importance of formulation aspects
por: van Riet-Nales, Diana A, et al.
Publicado: (2016)

PCSK9 Monoclonal Antibodies: An Overview
por: Kaddoura, Rasha, et al.
Publicado: (2020)

Can parents believe websites’ information about methylphenidate’s side effects?
por: Arsac England, Tom, et al.
Publicado: (2021)

Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis
por: Ruslami, Rovina, et al.
Publicado: (2022)

Assessment of mitochondrial toxicity in newborns and infants with congenital cytomegalovirus infection treated with valganciclovir
por: Ortiz-Gracia, Alba, et al.
Publicado: (2022)

Pharmacokinetics and tolerability of intranasal or intravenous administration of nalbuphine in infants
por: Pfiffner, Miriam, et al.
Publicado: (2023)

Point-of-care faecal calprotectin testing in patients with paediatric inflammatory bowel disease during the COVID-19 pandemic
por: Jere, Mwansa, et al.
Publicado: (2021)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
por: Mysler, Eduardo, et al.
Publicado: (2016)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Adherence patterns in naïve and prevalent use of infliximab and its biosimilar
por: Alanaeme, Chibuike J., et al.
Publicado: (2022)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
por: Subedi, Smriti, et al.
Publicado: (2019)

The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure–Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE Trial
por: Nguyen, Tu N., et al.
Publicado: (2021)

Epidemiology and Natural History of IBD in the Paediatric Age
por: Guariso, Graziella, et al.
Publicado: (2014)

PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Effect of Recombinant Human Parathyroid Hormone (1-84) on Resolution of Active Charcot Neuro-osteoarthropathy in Diabetes: A Randomized, Double-Blind, Placebo-Controlled Study
por: Petrova, Nina L., et al.
Publicado: (2021)

Biosimilars in Pediatric IBD: Updated Considerations for Disease Management
por: Dipasquale, Valeria, et al.
Publicado: (2022)

Randomized Outpatient Trial of Single- and Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors
por: Castle, Jessica R., et al.
Publicado: (2018)

Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA(1c), in Patients With Type 2 Diabetes
por: Ali, Ali Muhammed, et al.
Publicado: (2020)

Infliximab: the evidence for its place in therapy in ulcerative colitis
por: Van Assche, Gert, et al.
Publicado: (2007)

A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
por: Al-Salama, Zaina T.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hns11t1ej9o0beg426icitde3h